What Thess does

Thess Corporate is a French medical device company headquartered in Montpellier that builds connected products for medication intake security and medical telesurveillance. Its portfolio centers on two complementary devices: Thess Device, a connected and secure smart medication box with continuous integrity control, multi-fingerprint authentication (up to nine users), multi-medication management, and roughly one-month battery life; and Thess Monitoring, a configurable telemonitoring platform that meets French health-IT interoperability criteria (Agence Numérique Santé), integrates with Electronic Patient Records, and enables remote real-time medication dose adjustment by healthcare providers. A specialized variant, Thess Monitoring Antalgeek, extends the platform into post-surgical pain monitoring (ERAS and ambulatory surgery pathways). Thess was created in 2021 by La Sas La Valériane, which contributed its IT branch and the Thess Device research program with French patent FR3125962 in 2022.

The company operates a B2B enterprise model targeting healthcare institutions and clinical professionals rather than direct consumers. Go-to-market is anchored by direct enterprise sales and clinical-study partnerships with French teaching hospitals (CHU Montpellier, CHU Nîmes, CHU Grenoble), cancer networks (Unicancer, Institut de cancérologie du Gard), and dialysis providers (NephroCare), with international validation through Mayo Clinic (USA), NYC Pain Specialists (USA), CHU Montréal (Canada), and an AppMed distribution agreement covering Canada. Revenue combines one-time medical device sales with recurring telemonitoring services; in France, Thess Monitoring is reimbursed by Social Security under code 6654493 for nephrology telemonitoring (chronic renal insufficiency, hemodialysis, peritoneal dialysis, and post-renal transplant care), while other indications (oncology, post-surgical) are supported through clinical studies (Beautify, Prolife, Trace) without disclosed reimbursement. Regulatory status includes ISO 13485:2016 certification (DQS, 2024), CE DM Class IIa under MDR (EU) 2017/745, Convergence certification (2025), and RGPD/GDPR compliance, with industrialization and export supported by France 2030 and EU Next Generation EU public funding.

Name

Thess

Legal name

Thess Corporate

Website

https://thess-corp.fr

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Connected Medical Devices and Telemonitoring

NAICS

Offices of Physicians (6211), Health Care and Social Assistance (62)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Health Services (8000)

akta.pro primary industry

Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH)

Keywords

• Connected medical devices
• Medication adherence systems
• Medical telemonitoring
• Remote patient monitoring
• Healthcare IT solutions

Headquarters

HQ city

Montpellier

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales and Telemonitoring Services: Thess generates revenue through the sale of medical devices (Thess Device) and telemonitoring services (Thess Monitoring), with reimbursement from French social security for specific nephrology protocols including Stage IV, Stage V, hemodialysis, peritoneal dialysis, and post-renal transplant care.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Thess Corporate sells connected medical devices (Thess Device) for secure medication intake paired with Thess Monitoring, a configurable medical telesurveillance platform that lets healthcare providers remotely track patient adherence and adjust doses in real time. The portfolio also includes Thess Monitoring Antalgeek, a specialized telesurveillance variant for post-surgical pain monitoring, with the device line certified CE Class IIa under MDR (EU) 2017/745 and reimbursed by French social security for nephrology protocols.

Product overview

Thess Corporate offers a dual-product portfolio centered on digital medical devices for medication management and medical telemonitoring. Thess Device is the connected medication intake system (smart pill organizer) that secures and tracks medication-taking. Thess Monitoring is the accompanying telemonitoring platform that enables healthcare professionals to remotely track patient health and compliance. The two products are designed to work together: Thess Device provides precise compliance monitoring that feeds into Thess Monitoring's dashboard, enabling real-time notifications to care teams and caregivers when patients become non-adherent. A specialized variant, Thess Monitoring Antalgeek, addresses post-surgical pain monitoring.

Differentiator

Problem solved

Functional benefit

Brands

• Thess Device: Connected and secure medication intake medical device.
• Thess Monitoring

Products and services

• Thess Device Connected and secure medical device for medication intake. Enables real-time remote dose adjustment, manages multiple medications and dosages, supports up to 9 fingerprints for unlocking, has a one-month battery life on daily use, and maintains international connectivity for patients who travel.
• Thess Monitoring Configurable medical telesurveillance platform (CE Class IIa medical device) that enables healthcare professionals to remotely monitor patients' health parameters and medication adherence, supports notifications via SMS or email, and integrates with Electronic Patient Record systems.
• Thess Monitoring Antalgeek Specialized variant of Thess Monitoring dedicated to post-surgical pain monitoring, designed to secure patients' return home and prevent pain chronification after surgical procedures.

Quantifiable outcome

• Thess does not detract from human relationships with care teams; care team is actually more present with the technology
• +2 more outcomes

Named customers14 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Nine partnerships are on record, tiered core and major.

• AppMedcoreChannel Partner/ Reseller/ Distributor · 1 January 2025Thess Corporate and AppMed entered into a distribution agreement for Thess Monitoring and Thess Device in Canada, marking the company's first formal international distribution partnership.
• Centre Hospitalier de NîmescoreStrategic or Co-development PartnerCHU Nîmes partnered with Thess to pilot Thess Monitoring Antalgeek, a world-first digital medical device for post-surgical pain monitoring. The partnership aims to secure patient return home while preventing chronic pain risk.
• Mayo Clinic (USA)majorStrategic or Co-development PartnerMayo Clinic in the USA conducted usage experimentation of Thess Device starting in 2023 as part of international clinical validation.
• CHU Montréal (Canada)majorStrategic or Co-development PartnerCHU Montréal in Canada served as a usage experimentation site for Thess Device starting in 2025, supporting international expansion into the Canadian market.
• CHU GrenoblemajorStrategic or Co-development PartnerCHU Grenoble served as a usage experimentation site for Thess Device starting in 2025, validating the technology for medication compliance in French healthcare settings.
• NephroCaremajorStrategic or Co-development PartnerEuropean dialysis network partnership for nephrology telemonitoring services using Thess Monitoring for hemodialysis patients in center and at home settings.
• UnicancermajorStrategic or Co-development PartnerPartnership with the French cancer center network encompassing 18 comprehensive cancer centers, supporting oncology telemonitoring applications.
• Institut de cancérologie du GardcoreStrategic or Co-development PartnerRegional cancer institute partnership for medical telesurveillance using Thess products in oncology treatment protocols.
• CHU MontpelliercoreStrategic or Co-development PartnerMajor teaching hospital partnership for medical telesurveillance using Thess products across various therapeutic areas.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• MedMinder: Connected pill dispenser with remote monitoring and reminder functions for chronic and elderly patients, directly comparable to Thess Device's adherence and integrity-control features.
• Hillo (Aparito): Provides connected medication adherence and RPM solutions for clinical trials and patient monitoring, directly comparable to Thess Monitoring's telemonitoring platform with Electronic Patient Record integration.
• Pillsy (acquired by Becton Dickinson): Smart pill dispenser with companion app and adherence tracking, a direct product analog to Thess Device in the connected medication-adherence category.
• Devinlec / Observa: French-connected medication adherence and telemonitoring providers operating in similar remote patient monitoring and smart pillbox niches. Closely comparable to Thess in product offering and French reimbursement-driven business model.

Broad incumbents

• Philips (HealthSuite / RPM): Diversified medtech with remote patient monitoring and connected care platforms serving hospitals and home care. Overlaps with Thess Monitoring's telemonitoring platform and EHR integration capabilities.
• Doctolib (télésurveillance): French health-tech incumbent increasingly active in remote consultation and telemonitoring infrastructure for physicians and hospitals. Comparable as the dominant French healthcare software layer Thess must integrate with to scale.
• Bayer/Philips VitalConnect RPM solutions: Larger healthcare players offering RPM suites that can extend into medication adherence and chronic disease telemonitoring. Comparable as broad incumbents that could bundle or compete against Thess's specialty offering.
• Resmed (MDRP / remote monitoring): Global leader in connected health devices for chronic conditions (sleep apnea, COPD) with strong reimbursement and RPM infrastructure. Comparable as a broad incumbent moving into specialty medication adherence and remote patient monitoring.

Regional players

• Sencrop: French-connected device company illustrating the trajectory of European connected-device companies built around B2B sales and industrialisation. Relevant as a French tech peer in the same Montpellier/IoT ecosystem (different vertical).

Emerging players

• Huma (formerly Medopad): Digital health platform offering remote patient monitoring across multiple therapeutic areas including nephrology and oncology. Comparable as a software-focused RPM peer targeting similar clinical use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/thess_corporate

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Thess